Petvivo Holdings Inc

Company Overview

Business Model: PetVivo Holdings, Inc. is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The Company's primary revenue generation mechanism involves the sale of its lead product, Spryng® with OsteoCushion® Technology, a veterinarian-administered intraarticular injection for joint afflictions in dogs and horses, and the licensing of other proprietary products. The Company leverages technology initially developed for human biomedical applications to efficiently commercialize treatments for companion animals.

Market Position: The Company operates in the animal health market, specifically targeting the osteoarthritis market in dogs and horses. Osteoarthritis affects approximately 14 million dogs and 1.1 million horses in the U.S. The Company positions Spryng® as an alternative to traditional treatments (like NSAIDs, steroids, and hyaluronic acid injections) by addressing the underlying cause of joint deterioration rather than just symptoms. Spryng® is designed to provide a bio-integrative scaffold, mimicking natural cartilage, and has shown long-lasting multi-month improvement in lameness with minimal adverse side effects. The product is veterinarian-administered, aiming to expand practice revenues and margins for veterinary clinics.

Recent Strategic Developments:

• Product Commercialization: Commenced sales of Spryng® in the second quarter of fiscal 2022.
• Distribution Partnerships:
  • Initially entered an exclusive distribution agreement with MWI in June 2022, which transitioned to non-exclusive in December 2023 and was mutually terminated in March 2025.
  • Entered a non-exclusive distribution agreement with Covetrus North America, LLC in December 2023, which was mutually terminated in February 2025.
  • Established new wholesale distribution partnerships with Vedco Inc. and Clipper Distributing, LLC in December 2024.
• Licensing Agreement: Signed an exclusive licensing agreement with VetStem, Inc. in February 2025 to market and sell their Precise PRP (Platelet-Rich Plasma) product for canine and equine, with revenues expected in fiscal year 2026.
• Clinical Studies: Completed a university clinical study with Colorado State University in March 2024. Successfully completed an equine tolerance study in March 2022. Initiated two canine clinical studies with Ethos Veterinary Health, with the first completed in October 2023 and the second expected to complete in October 2024.
• Manufacturing Expansion: A second ISO cleanroom facility is expected to be operational later in fiscal year 2025 to minimize supply risks, scale production capacity, and expand R&D facilities.

Geographic Footprint: The Company's primary operational and commercialization efforts are focused within the United States. Its corporate headquarters and manufacturing facilities are located in Edina and Minneapolis, Minnesota.

Financial Performance

Revenue Analysis

Profitability Metrics (FY2025):

• Gross Margin: 87.8%
• Operating Margin: -711.3%
• Net Margin: -741.6%

Investment in Growth (FY2025):

• R&D Expenditure: $1,583,250 (139.8% of revenue)
• Capital Expenditures: $63,434 (for property and equipment)
• Strategic Investments: $500,000 cash payment for the exclusive licensing agreement with VetStem, Inc.

Business Segment Analysis

Animal Health Products

Financial Performance (FY2025):

• Revenue: $1,132,533 (+16.9% YoY)
• Operating Margin: -711.3% (reflecting consolidated operating loss as the Company operates as one segment)
• Key Growth Drivers: Increased sales of Spryng® product, particularly through new distribution partnerships with Vedco Inc. and Clipper Distributing, LLC, and the exclusive licensing agreement with VetStem, Inc. for Precise PRP.

Product Portfolio:

• Spryng® with OsteoCushion® Technology: A veterinarian-administered intraarticular injection for the management of lameness and osteoarthritis in dogs and horses. It is designed to provide a bio-integrative scaffold, mimicking natural cartilage.
• Precise PRP (Platelet-Rich Plasma): An exclusive licensed product from VetStem, Inc. for canine and equine applications, with revenues expected in fiscal year 2026.
• Innovation Pipeline: Includes 17 therapeutic devices for both veterinary and human clinical applications, such as dermal fillers (CosmetaLife®), cardiovascular devices (VasoGraft®, VasoCover™), drug delivery systems, and orthopedic devices (OrthoGelic™, OrthoMetic™) for non-union broken bones.

Market Dynamics:

• The Company targets the companion animal veterinary care market, specifically the osteoarthritis segment in dogs and horses.
• Osteoarthritis is a common, progressive, and degenerative joint disease affecting approximately 14 million dogs and 1.1 million horses in the U.S.
• Current veterinary treatments for osteoarthritis often only address symptoms (e.g., NSAIDs, steroids, hyaluronic acid injections) and may have side effects. Spryng® offers a treatment that addresses the affliction itself.
• The Company's products are veterinarian-administered medical devices, which are positioned to help veterinary practices replace lost prescription revenues and expand margins.

Sub-segment Breakdown (FY2025 Revenue Contribution):

• MWI Veterinary Supply Co.: $430,818 (38% of total revenue)
• Covetrus North America, LLC: $44,015 (4% of total revenue)
• Vedco Inc.: $288,929 (26% of total revenue)
• Clipper Distributing, LLC: $194,504 (17% of total revenue)
• Direct Sales to Veterinary Clinics: $176,374 (15% of total revenue)

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None disclosed.
• Dividend Payments: The Company has never declared or paid any cash dividends on its common stock and anticipates retaining all earnings for business plan implementation and future growth.
• Future Capital Return Commitments: Not applicable.

Balance Sheet Position (as of March 31, 2025):

• Cash and Equivalents: $227,689
• Total Debt: $3,350,312 (includes notes payable, convertible notes payable, derivative liabilities, and operating lease liabilities)
• Net Cash Position: ($3,122,623)
• Credit Rating: Not disclosed.
• Debt Maturity Profile:
  • Notes Payable: $312,865 due in FY2026, $5,442 due in FY2027.
  • Convertible Notes Payable: $1,772,021 (all current liability) due by December 31, 2025.
  • Operating Lease Liabilities: $163,834 current portion, $797,705 non-current portion.

Cash Flow Generation (FY2025):

• Operating Cash Flow: ($5,321,953)
• Free Cash Flow: ($5,385,387) (Operating Cash Flow less $63,434 in capital expenditures)
• Cash Conversion Metrics: Not explicitly detailed, but the Company has experienced negative cash flows from operations.

Operational Excellence

Production & Service Model: The Company manufactures its products in an ISO 7 certified clean room manufacturing facility in Minneapolis. It utilizes a patented and scalable self-assembly production process designed to minimize infrastructure requirements and manufacturing risks, ensuring consistent, high-quality products responsive to volume requirements. A second ISO cleanroom facility is expected to be operational later in fiscal year 2025 to further enhance production capacity and minimize supply risks.

Supply Chain Architecture: Key Suppliers & Partners:

• Raw Materials: The Company relies on independent third parties to produce raw materials such as collagen, elastin, and heparin.
• Manufacturing Partners: Not explicitly mentioned, but the Company manufactures its own products.
• Technology Partners: VetStem, Inc. for the exclusive licensing of Precise PRP.

Facility Network:

• Manufacturing: Operates an ISO 7 certified clean room manufacturing facility in Minneapolis, with a second facility expected to be operational soon.
• Research & Development: R&D facilities are expected to expand with the second cleanroom.
• Distribution: Leases approximately 3,600 square feet of office, laboratory, and warehouse space, an additional 2,400 square feet of office space, and 14,073 square feet of production and warehouse space in Edina, Minnesota.

Operational Metrics: The Company emphasizes its scalable production process to deliver consistent, high-quality products and be responsive to volume requirements. Specific quantitative operational metrics like capacity utilization or efficiency rates are not disclosed.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: The Company engages in direct sales to veterinarians.
• Channel Partners:
  • MWI Veterinary Supply Co.: Previously an exclusive, then non-exclusive, distributor (agreement terminated March 2025).
  • Covetrus North America, LLC: Previously a non-exclusive distributor (agreement terminated February 2025).
  • Vedco Inc. and Clipper Distributing, LLC: New wholesale distribution partnerships established in December 2024, both leaders in logistical solutions and supply to veterinarians.
• Digital Platforms: The Company sells via the internet to customers not directly solicited by distributors.

Customer Portfolio: Enterprise Customers: The Company primarily targets licensed veterinary practices. Customer Concentration: In fiscal year 2025, 38% of total revenues were generated from sales under the MWI distribution partnership, 4% from Covetrus North America, LLC, 26% from Vedco Inc., and 17% from Clipper Distributing, LLC.

Geographic Revenue Distribution:

• United States: All reported revenues are from the United States.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The animal health market is described as a strong component of the U.S. economy and more resistant to economic cycles. The veterinary sector is attractive due to its growth and lack of reimbursement risk. The U.S. pet care market was $123.6 billion in 2021, with veterinary care and product sales constituting $34.3 billion. The market is driven by increasing pet ownership (70% of U.S. households in 2022). Osteoarthritis is a significant concern, affecting approximately 14 million adult dogs and 1.1 million horses in the U.S.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The animal health market is highly competitive, with significant competition from major pharmaceutical, biotechnology, and specialty animal health companies.

• Large Animal Health Companies: Zoetis, Inc.; Merck Animal Health; Merial (Sanofi S.A.); Elanco (Eli Lilly and Company); Bayer Animal Health (Bayer AG); Novartis Animal Health (Novartis AG); Boehringer Ingelheim Animal Health; Virbac Group; Ceva Animal Health; Vetoquinol; Dechra Pharmaceuticals PLC.
• Smaller/Emerging Companies: Kindred Bio, Aratana Therapeutics Inc. (acquired by Elanco), NextVet, VetDC.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions are ongoing threats in the dynamic animal health industry.

Competitive Response Strategy: The Company's strategy involves increasing commercialization efforts for Spryng® through sales representatives, clinical studies, and market awareness to educate key opinion leaders. It also plans to expand its product pipeline through acquisition or in-licensing of additional proprietary products and may establish strategic out-licensing partnerships for secondary revenues.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company faces risks related to its limited operating history and substantial losses incurred to date. Its future prospects are heavily dependent on the successful market acceptance and commercialization of Spryng®, which requires educating veterinarians and pet owners, managing potential side effects, maintaining regulatory compliance, and enforcing intellectual property rights. Technology Disruption: Competition from alternative, more effective, or lower-cost treatments offered by competitors, as well as the emergence of new products or technologies, could impact market penetration. Customer Concentration: The Company relies on distribution partnerships for a significant portion of its revenues, and the loss or termination of these agreements could adversely affect financial performance.

Operational & Execution Risks

Supply Chain Vulnerabilities: The Company relies on independent third parties for raw materials (collagen, elastin, heparin) and is dependent on their services, which could be impaired by circumstances outside its control. Capacity Constraints: Rapid commercial growth of Spryng® could place significant demands on management and operational/financial resources, potentially leading to difficulties in managing growth effectively. Distribution Agreement Loss: The Company has experienced terminations of distribution agreements with MWI and Covetrus North America, LLC, highlighting the risk of losing key distribution channels. Talent Management: Success is highly dependent on attracting and retaining qualified management and key scientific personnel, with intense competition for such talent. Natural Disasters & External Events: Operations are subject to interruption by natural disasters, power shortages, pandemics, and other events beyond control, which could disrupt business and decrease demand.

Financial & Regulatory Risks

Market & Financial Risks: The Company has incurred substantial losses and has limited cash reserves, raising substantial doubt about its ability to continue as a going concern. It requires significant additional financing to fund operations and expansion, with no assurance of availability on acceptable terms. The market price of its common stock is highly volatile, and past delisting from Nasdaq (now trading on OTCQB) and potential classification as a "penny stock" could limit liquidity and investor interest. Regulatory & Compliance Risks:

• Product Approval: While Spryng® is classified as a veterinary medical device and does not require pre-market approval by the FDA in the U.S., future products for veterinary or human applications may require rigorous regulatory approvals (e.g., 510(k), PMA from FDA, CE Mark in EU, CVM, USDA, state authorities). Delays or denials of such approvals could significantly harm commercialization efforts.
• Compliance: The Company is subject to FDA quality system regulations, restrictions on "off-label" promotion, and federal healthcare laws (False Claims Act, Anti-Kickback Statute, Stark law, healthcare fraud statutes) and comparable state laws. Non-compliance could lead to severe penalties.
• Internal Controls: Management concluded that internal control over financial reporting was not effective as of March 31, 2025, due to a material weakness related to derivative liabilities and warrant discount with convertible notes.

Geopolitical & External Risks

Geographic Dependencies: Not explicitly detailed beyond U.S. focus. Trade Relations: Exported devices are subject to regulatory requirements of each country, and changes in trade relations or policies could impact international expansion. Sanctions & Export Controls: Compliance with international regulations is required for any future international business.

Innovation & Technology Leadership

Research & Development Focus: The Company is actively pursuing advancements in the composition, methods of manufacture, and use of its proprietary biomaterials. Future R&D efforts include additional third-party studies for Spryng® in canine and equine osteoarthritis, improving manufacturing systems for Spryng® to increase volume and efficiency, and identifying new commercial products from existing formulations (e.g., for navicular disease in horses).

Core Technology Areas:

• Proprietary Biomaterials: Based on natural protein and carbohydrate compositions, incorporating collagen, elastin, and proteoglycans (like heparin). These biomaterials are designed to simulate cellular tissue, offering enhanced biocompatibility and bio-integration.
• Self-Assembly Production Process: A patented and scalable manufacturing process used in ISO 7 certified clean rooms.

Innovation Pipeline: The Company has a pipeline of 18 products, including 17 therapeutic devices for both veterinary and human clinical applications.

• Dermal Filler: CosmetaLife®, a water-protein-based dermal filler for wrinkle treatment, which completed an FDA clinical trial (NCT00414544) and showed long-term dermal contouring and rejuvenation with minimal adverse effects.
• Cardiovascular Devices: Blood-compatible biomaterials for cardiovascular tissue repair, including VasoGraft® (a blood vessel graft made from VasoCover™ material).
• Drug Delivery: Unique fabrication techniques for homogeneous drug distribution in various delivery methods (coatings, injectables, implantables, transmucosal delivery).
• Orthopedic Devices: Materials for orthopedic and dental applications, including OrthoGelic™ and OrthoMetic™ for difficult-to-heal, non-union broken bones.

Intellectual Property Portfolio:

• Patent Strategy: A portfolio of 12 patents (6 issued in the U.S., 2 U.S. applications pending, 4 granted internationally in Canada and the European Union) protecting biomaterials, products, production processes, and methods of use. Key U.S. patents include those for biocompatible protein-based particles, protein biomaterials, and vessel graft systems.
• Licensing Programs: The Company may establish strategic out-licensing partnerships for secondary revenues. An exclusive licensing agreement with VetStem, Inc. for Precise PRP was signed in February 2025.
• Trade Secrets: Six documented trade secrets covering unique ingredient compositions, specialized blending and production techniques, quality control procedures, and process efficiencies.
• Trademarks & Copyrights: Owns U.S. federally registered trademarks Spryng® and OsteoCushion®, asserts common law rights in PetVivo™, and owns various copyrights for product documentation, website content, and marketing materials.

Technology Partnerships:

• Strategic Alliances: Exclusive licensing agreement with VetStem, Inc. for Precise PRP.
• Research Collaborations: Clinical trial services agreement with Colorado State University and canine clinical studies with Ethos Veterinary Health.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company's success is significantly dependent on its current management and key scientific technicians, and its ability to attract, retain, and motivate future personnel. The loss of key personnel could delay or prevent successful commercialization or product development.

Board Composition: The Board of Directors consists of six independent members: Spencer Breithaupt (Chair of Nominating and Governance Committee), Robert Costantino (Chair of Audit Committee), Joseph Jasper (Chair of Compensation Committee), Diane Levitan, Robert Rudelius (Chairman of the Board), and Michael Eldred. The Board administers cybersecurity risk oversight directly and through the Audit Committee.

Human Capital Strategy

Workforce Composition: As of July 10, 2025, the Company has 24 employees. It also engages outside consultants for R&D, clinical development, regulatory matters, investor relations, and operations.

Talent Management: Acquisition & Retention: The Company believes its success depends on attracting, developing, and retaining key personnel, offering competitive compensation and benefits. Employee Value Proposition: The Company offers health insurance and a 401(k) plan to eligible employees, along with vacation and paid holidays.

Diversity & Development: Not explicitly detailed in the filing. Culture & Engagement: The Company believes its relationships with employees are good.

Regulatory Environment & Compliance

Regulatory Framework: The Company's medical devices are subject to regulation by numerous bodies, including the FDA and comparable international agencies. Industry-Specific Regulations:

• U.S. Veterinary Devices: Spryng® is classified as a veterinary medical device and does not require pre-market approval (510(k) or PMA) from the FDA for its current intended uses. However, the FDA retains regulatory oversight and can take action if a device is misbranded or adulterated.
• U.S. Human/Future Veterinary Devices: Other pipeline products for human or future veterinary applications may require 510(k) clearance or PMA from the FDA, involving extensive data submission and clinical trials.
• International Compliance: In the EU, devices must comply with the Medical Devices Directive and obtain CE Mark certification (Class IIa or IIb). Other countries, like Japan, may require Ministry of Health Labor and Welfare approval.
• Quality Systems: The Company is subject to FDA's quality system regulations governing design, manufacture, packaging, and servicing of medical devices.
• Promotion & Advertising: Prohibited from promoting "off-label" uses.
• Healthcare Laws: Subject to federal healthcare laws (False Claims Act, Anti-Kickback Statute, Stark law, healthcare fraud statutes) and similar state laws, particularly if products are reimbursed under government programs.
• Foreign Corrupt Practices Act: Applicable to arrangements with foreign government officials.

Trade & Export Controls: Exported devices are subject to the regulatory requirements of each destination country.

Legal Proceedings: As of March 31, 2025, there were no pending or threatened legal actions expected to have a material adverse effect. A settlement agreement with a former director, David Masters, for $180,000 was paid in October 2023.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company's effective tax rate is 0% due to a full valuation allowance against deferred tax assets.
• Net Operating Loss Carryforwards: As of March 31, 2025, the Company had approximately $44,300,000 in net operating loss carryforwards.
• Valuation Allowance: A full valuation allowance of $14,678,000 is provided against total deferred tax assets, as management deems it uncertain whether the Company can utilize these assets in future periods.
• Geographic Tax Planning: The Company is subject to taxation in the U.S. and Minnesota.